Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

@article{Druker2001EfficacyAS,
  title={Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.},
  author={Brian J. Druker and Moshe Talpaz and Debra Resta and Bin Peng and Eliasbeth Buchdunger and John M. Ford and Nicholas Lydon and Hagop M Kantarjian and Renaud Capdeville and S Ohno-Jones and Charles L Sawyers},
  journal={The New England journal of medicine},
  year={2001},
  volume={344 14},
  pages={
          1031-7
        }
}
BACKGROUND BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML. METHODS We conducted a phase 1, dose-escalating trial of STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase. STI571 was administered orally to 83 patients with CML in the chronic phase in whom… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 2,120 CITATIONS, ESTIMATED 54% COVERAGE

16 Hematopoietic Stem Cells Therapeutic Applications

VIEW 15 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Nose‐to‐brain transport of imatinib mesylate: A pharmacokinetic evaluation

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia

VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate

VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Unique molecular characteristics of radiation-induced glioblastoma.

VIEW 13 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Lack of clinical efficacy of imatinib in metastatic melanoma

VIEW 7 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Imatinib Mesylate

VIEW 14 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Targeted blocking of miR328 lysosomal degradation with alkalized exosomes sensitizes the chronic leukemia cells to imatinib

VIEW 13 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

1999
2020

CITATION STATISTICS

  • 144 Highly Influenced Citations

  • Averaged 75 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 21 REFERENCES

Current status of treatment for chronic myelogenous leukemia

  • KS Kolibaba, BJ Druker
  • Medscape Oncology
  • 2001

Chronic myeloid leukemia.

The biology of chronic myeloid leukemia.